Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Kanagathara Nachiappan

Kanagathara Nachiappan

Sri Lakshmi Narayana Institute of Medical sciences, India

Title: Targeted drug delivery system of 5 - Fluorouracil with recombinant epidermal growth factor for brain tumor

Biography

Biography: Kanagathara Nachiappan

Abstract

5 Fluorouracil is an anticancer drug which has it effects on colon cancer, brain tumor, breast cancer, head & neck cancer. The aim of the present study was to formulate, optimize, and characterize 5 fluorouracil nanoemulsions for targeting brain tumor. The components of the formulation were optimized. The solubility study for the oil in surfactant & co-surfactant mix ratio was optimized. The characterization studies such as physical appearance, Dispersibility study, Density, Viscosity, pH, Surface tension, Globule size & Poly dispersity index, In vitro drug release, Thermodynamic stability were performed for all the ten formulations. Zeta potential, Optical microscopic analysis and Transmission electron microscopic analysis were done for the selected formulation. Based on the results of characterization NE3 was selected for conjugation with EGF. Two different methods such as physical mixing, solvent evaporation technique was done for conjugation of Epidermal growth factor with drug and physical mixing technique was optimized as the best method for conjugating the formulation. 5 Flurouracil nanoemulsions for targeting brain tumor and the pseudo ternary phase diagram for the solubility studies and the components of different phases were optimized and characterized through this study. The targeting efficiancy of the drug was studied by molecular docking for conjugated drug formulation and the binding energy level of Drug Conjugated Formulation with Epidermal Growth Factor is high when compared with the plain drug.